Diwakar Davar

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Diwakar Davar sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials 5 currently recruiting 5 completed early-phase tilt top decile by trial count

Diwakar Davar: 12 sponsored US clinical trials, 5 recruiting.

Diwakar Davar sponsors 12 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Melanoma, with 3 trials.

Top-decile sponsor footprint

Diwakar Davar ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

12 total, page 1 of 1

RECRUITING Phase 2

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

NCT07223424
RECRUITING Phase 2

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

NCT06070012
RECRUITING Phase 2

Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC)

NCT06499896
RECRUITING Phase 2

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

NCT05669846
RECRUITING Phase 2

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

NCT05130177
ACTIVE NOT RECRUITING Phase 2

Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)

NCT04808999
ACTIVE NOT RECRUITING Phase 2

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

NCT04139902
COMPLETED Phase 2

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

NCT05061017
COMPLETED Phase 2

Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab

NCT04401995
COMPLETED Phase 2

CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease

NCT03618641
COMPLETED Phase 1

Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma

NCT01608594
COMPLETED Early Phase 1

Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma

NCT00972933

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 10

Therapeutic Areas

Melanoma 3
Squamous Cell Carcinoma 2
Non-Small Cell Lung Cancer 2
Gastric/GEJ 1
Colo-rectal Cancer (dMMR/MSI-H CRC) 1
Immune-related Dermatitis 1
Immune-mediated Colitis (IMC) 1
Uveal Melanoma 1
Melanoma Stage IV 1
Melanoma Stage III 1

What is open in the Diwakar Davar pipeline

5 recruiting of 12 indexed (42% open); 5 completed (42%).

Phase mix: 0 late (III/IV) vs 12 early (I/II) (early-phase heavy).

Top condition: Melanoma (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Diwakar Davar: open-pipeline peers nationwide

Peers matched on 12 registered trials and 42% open enrollment, not the therapeutic-area sidebar.

Diwakar Davar sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 10152025 0%10%20%30%40%50% Total trials Recruiting share Diwakar DavarAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.AngiodynamicsArthrexExactechInari MedicalMassachusetts Institute of Technology
Diwakar Davar sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Diwakar Davar sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 trials (± recruiting share)

Sponsors near 42% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Diwakar Davar page

12 registered trials is a research-attention snapshot, not an endorsement of Diwakar Davar or any single study.

  • 5 of Diwakar Davar's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Melanoma is the condition Diwakar Davar studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Melanoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Diwakar Davar pipeline card: 12 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.